Hengrui Usa company information, Employees & Contact Information

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology GSK

GSK, China's Jiangsu Hengrui strike $500 million drug-development deal Reuters

In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu Fierce Pharma

GSK strengthens COPD offering via $12B biobucks, 12-program deal with China's Hengrui Pharma Fierce Biotech

Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals statnews.com

GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects South China Morning Post

FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again Fierce Pharma

Allosteric CDC37 Inhibitor Disrupts Chaperone Complex to Block CDK4/6 Maturation Wiley Online Library

ESMO 2024: Can Jiangsu Hengrui Pharma disrupt the HER2-mGEJ treatment paradigm? Clinical Trials Arena

Glenmark Pharma inks cancer drug licensing deal with Hengrui Pharma; check details Upstox

Hengrui Oncology Collaboration | Merck Merck Group

Hengrui Pharma’s HK$9.89 Billion IPO: A Strategic Move to Cement Global Pharmaceutical Leadership Minichart

Desymmetric Hydrogenation of meso -Dicarboxylic Acids ACS Publications

Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+ BioSpace

Investors put $400M into biotech licensing obesity drugs from China BioPharma Dive

GSK, Hengrui Sign $500M Drug Development Pact Contract Pharma

Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme | Journal of Medicinal Chemistry ACS Publications

Can Hengrui become a global pharmaceutical giant like Merck after its Hong Kong IPO? South China Morning Post

Fierce Pharma Asia—Celltrion's Lilly plant buy; Rexulti's PTSD snub; Glenmark, Hengrui's ADC deal Fierce Pharma

Fierce Pharma Asia—Pfizer partner's trial win; Roche's $300M China plant; Hengrui's HK IPO plan Fierce Pharma

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug South China Morning Post

Hengrui, Kailera say dual-acting obesity shot succeeds in China study BioPharma Dive

GSK, Hengrui Focus on Cancer, Respiratory Diseases, I&I in Up-to-$12.5B Collaboration Genetic Engineering and Biotechnology News

Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push Fierce Biotech

Hengrui Pharmaceuticals Is Said to Weigh Second Listing in Hong Kong Bloomberg.com

FDA cracks down on China's Hengrui in scathing manufacturing write-up Fierce Pharma

China’s Hengrui gets boost from fifth drug-licensing deal of year South China Morning Post

Merck, Hengrui Launch Up-to-$2B+ Cardiometabolic Collaboration Genetic Engineering and Biotechnology News

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits South China Morning Post

Effect of CYP3A4 Induction and Inhibition on the Pharmacokinetics of SHR0302 in Healthy Subjects British Pharmacological Society | Journals

Hengrui and Glenmark sign $1B deal for HER2-targeting ADC BioWorld MedTech

Development of Asymmetric Reductive Amination of Unfunctionalized Ketone with Primary Amine ACS Publications

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects Frontiers

How Innovative Is China in Biotechnology? Information Technology and Innovation Foundation

Eyes on Asia: GSK & Hengrui, Novatim, Pfizer BioXconomy

Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion Bloomberg.com

Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 BioWorld MedTech

Behind Hengrui's surprise FDA rejection: Scathing Form 483 lists litany of shortfalls at PD-1 drug plant Fierce Pharma

Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial Fierce Biotech

Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III BioSpace

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor Frontiers

Jiangsu Hengrui jumps 25% in solid Hong Kong trading debut South China Morning Post

FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo Fierce Pharma

Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease ACS Publications

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart Citeline News & Insights

Jiangsu Hengrui Pharma and Elevar Therapeutics Announce GlobeNewswire

HLB acquires global rights to camrelizumab for liver cancer from Jiangsu Hengrui Pharmaceuticals koreabiomed.com

Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor ACS Publications

Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years Law.asia

Hengrui licenses EZH2 inhibitor to Treeline in $700M deal BioWorld MedTech

Fast Isomerization Before Isomerization-Hydroformylation: Probing the Neglected Period with A Novel Microfluidic Device Wiley Online Library

'Startup like no other': China's Hengrui launches Luzsana with Big Pharma veterans at the top and a goal to improve drug access Fierce Pharma

Hengrui Pharma accelerates bid for global brand status thebambooworks.com

Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis ACS Publications

Protein Phosphatase 5-Recruiting Chimeras for Accelerating Apoptosis-Signal-Regulated Kinase 1 Dephosphorylation with Antiproliferative Activity ACS Publications

Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity | Journal of Medicinal Chemistry ACS Publications

Hengrui Pharma targets obesity drug launch after test success thebambooworks.com

China's Jiangsu Hengrui to grant license for cancer drug to unit of India's Glenmark The Standard (HK)

Hengrui's Sun Piaoyang, China's richest pharma leader, steps down after 30-year run—sort of Fierce Pharma